← SynDRA
ELINOGREL
SynDRA canonical compound SYN0030032 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | P2RY12 |
|---|
| Mechanism of action | purinergic receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- P2RY12 ANTAGONIST
- Purinergic receptor P2Y12 antagonist
- purinergic receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADGRF1
- ADRA2A
- ADRB2
- AGTR1
- APLNR
- C5AR1
- CX3CR1
- FFAR4
- FPR2
- GLP1R
- GPR119
- GPR35
- HDAC6
- S1PR1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- Prt060128
- PRT-060128
- UNII-915Y8E749J
- 915Y8E749J
- 5-CHLORO-N-[[[4-[6-FLUORO-1,4-DIHYDRO-7-(METHYLAMINO)-2,4-DIOXO-3(2H)-QUINAZOLINYL]PHENYL]AMINO]CARBONYL]-2-THIOPHENESULFONAMIDE
- PRT 060128
- Elinogrel [USAN:INN]
- Elinogrel (USAN/INN)
- SCHEMBL160663
- CHEMBL2103828
- MolPort-035-941-202
- ZINC43153259
- BDBM50397204
- AKOS025142086
- NCGC00387478-01
- AN-26210
- FT-0724857
- D09607
- 500C946
- 1-(5-chlorothiophen-2-yl)sulfonyl-3-[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1H-quinazolin-3-yl]phenyl]urea
- PRT060128
- elinogrelum
- RefChem:590713
- DTXCID501347216
- ELINOGREL [INN]
- ELINOGREL [MI]
- ELINOGREL [USAN]
- ELINOGREL [WHO-DD]
- orb1309711
- SCHEMBL31722301
- GLXC-06125
- HY-11021
- MS-29701
- DB-079641
- CS-0002993
- NS00072515
- G13885
- BRD-K59271229-001-01-5
- PRT 060128; PRT-060128; PRT060128; Elinogrel
Look up ELINOGREL in the interactive SynDRA portal →